PROVEN REDUCTION OF VTE RISK1
Once-daily LIXIANA® (edoxaban) effectively prevented symptomatic recurrent VTE (including DVT and fatal and nonfatal PE) across a broad range of eligible patients.1
Symptomatic recurrent VTE included deep vein thrombosis (DVT) and fatal and nonfatal pulmonary embolism (PE).
Proven efficacy compared with a well-managed warfarin arm
- Eligible patients taking warfarin were in the therapeutic INR range (2.0 to 3.0) for 63.5% of the time